In a report released today, Tara Bancroft from TD Cowen maintained a Buy rating on Geron (GERN – Research Report), with a price target of $10.00. Tara Bancroft has given
In a report released today, Tara Bancroft from TD Cowen maintained a Buy rating on Geron (GERN – Research Report), with a price target of $10.00. Tara Bancroft has given
Reports Q2 revenue $882,000, consensus $270,000. “We are thrilled to have begun the launch of RYTELO, our first commercial product, in June, and are encouraged by the early success we
Geron Corporation (GERN) is scheduled to report 2nd quarter earnings on 08/08/2024, before the market opens. Regarding Q2 estimates, Wall Street analysts expect Geron Corporation to post earnings of -$0.10
Geron announced that the National Comprehensive Cancer Network, or NCCN, has updated its Clinical Practice Guidelines in Oncology, or NCCN Guidelines, for the treatment of Myelodysplastic Syndromes, or MDS, to
In a report released today, Stephen Willey from Stifel Nicolaus maintained a Buy rating on Geron (GERN – Research Report), with a price target of $7.00. The company’s shares closed